Full QT study for once-weekly Bydureon comes out clean, as expected, paving way for NDA resubmission
This article was originally published in Scrip
Amylin, Lilly and Alkermes have given Wall Street more good news about once-weekly Bydureon, the glucogen-like peptide-1 agonist exenatide in type 2 diabetes, still under review by US regulators. It was not a surprise to many, but Amylin announced that the FDA-required full QT study confirmed that Bydureon, at and above therapeutic levels, did not prolong corrected QT (QTc) interval in healthy volunteers, nor did not it show dose-dependent increase in QTc interval at higher dose levels.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.